Study Of Asthma In Patients Of African Descent

GlaxoSmithKline (GSK)

Status and phase

Completed

Phase 4

Conditions

Asthma

Treatments

Drug: fluticasone propionate/salmeterol powder

Drug: fluticasone propionate powder

Study type

Interventional

Funder types

Industry

Identifiers

NCT00102765

SFA103153

Details and patient eligibility

About

This study will last up to 62 weeks. You will visit the clinic up to 17 times. Certain clinic visits will include physical examination, medical history review and lung function tests. The purpose of this study is to see if one asthma drug (fluticasone propionate/salmeterol) is better in reducing the number of asthma exacerbations compared with another drug (fluticasone propionate alone)

Enrollment

479 patients

Sex

All

Ages

12 to 65 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

History of asthma for at least 6 months.
Taking a low-dose of an inhaled corticosteroid for at least one month prior to the study (such as fluticasone propionate or budesonide).

Exclusion criteria

History of life-threatening asthma.
Hospitalized for asthma within 3 months prior to the study.
Current respiratory tract infection.
Will not be able to attend clinic visits for the entire length of the study.
Certain medical conditions that will make being in the study unsafe (such as congestive heart failure, uncontrolled hypertension, tuberculosis or certain drug allergies).